Alkem signs licensing agreement with Harvard University’s Office of Technology Development


Alkem Laboratories has signed a licensing agreement with Harvard University’s Office of Technology Development (OTD) allowing Alkem to develop and commercialize a new technology that could help meet the urgent need for an effective treatment of diabetic neuropathy, foot ulcers, peripheral arterial disease (PAD), and other injuries caused by vascular disease.

The license grants Alkem commercialization rights in the United States and India.

Powered by Capital Market – Live News




(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear reader,

Business Standard has always endeavored to provide up-to-date information and commentary on developments that matter to you and that have wider political and economic implications for the country and the world. Your constant encouragement and feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these challenging times stemming from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative opinions and incisive commentary on relevant topical issues.
However, we have a request.

As we battle the economic impact of the pandemic, we need your support even more so that we can continue to bring you more great content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.

Support quality journalism and subscribe to Business Standard.

digital editor